New drugs 2012, part 2.
Pharmacy Philadelphia College of Pharmacy University of the Sciences in Philadelphia Philadelphia, Pa, USA.
Daniel A
DA
Hussar
D000069594:Abatacept; D000241:Adenosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000617:Aminoglycosides / Q000627:therapeutic use; D001920:Bradykinin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077543:Deferiprone; D017277:Drug Approval; D000077732:Fidaxomicin; D013007:Growth Hormone-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D009025:Morpholines / Q000627:therapeutic use; D009570:Nitriles / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D000068696:Rilpivirine; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use; D000077486:Ticagrelor
D000617:Aminoglycosides; D018796:Immunoconjugates; D009025:Morpholines; D009570:Nitriles; D011728:Pyridones; D011743:Pyrimidines; D011993:Recombinant Fusion Proteins; D013876:Thiophenes; C533178:aflibercept; D000077543:Deferiprone; D000069594:Abatacept; C065679:icatibant; D013007:Growth Hormone-Releasing Hormone; D000069552:Rivaroxaban; D040262:Receptors, Vascular Endothelial Growth Factor; D000068696:Rilpivirine; D000077486:Ticagrelor; D000241:Adenosine; C479538:tesamorelin; D001920:Bradykinin; D000077732:Fidaxomicin